

18 September 2025

**Our Ref:** FOI 1309

Dear

**Freedom of Information Act 2000  
Information in Relation to Number of Patients Receiving Treatment with  
Listed Diseases**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above, which you requested on 25 July 2025. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to the questions you have raised has been provided by the Surgery, Elective Care, Maternity and Paediatrics Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital ([informationgovernance@setrust.hscni.net](mailto:informationgovernance@setrust.hscni.net)) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

---

**Olivia Robinson**  
**Information Governance Officer**

**Q1. In the past 3 months [latest 3 months available] how many patients have received the following treatments [for any disease]:**

- **Beriner** (Human C1-esterase inhibitor)
- **Cinryze** (Human C1-esterase inhibitor)
- **Orladeyo** (Berotralstat)
- **Takhzyro** (Lanadelumab)
- **Ruconest** (Recombinant human C1-esterase inhibitor)
- **Firazyr** (Icatibant injection)
- **Icatibant** - any brand except Firazyr

A1. Please see Table 1 below for the number of patients that have received the listed treatments in the past 3 months.

Table 1

<b>Treatment</b>	<b>Number of Patients</b>
Beriner (Human C1-esterase inhibitor)	Nil
Cinryze (Human C1-esterase inhibitor)	Nil
Orladeyo (Berotralstat)	Nil
Takhzyro (Lanadelumab)	Nil
Ruconest (Recombinant human C1-esterase inhibitor)	Nil
Firazyr (Icatibant injection)	Nil
Icatibant - any brand except Firazyr	Nil

**Q2. In the past 3 months how many patients have received the following treatment for any disease:**

- **Octagam**
- **Gamunex**
- **Intratect**
- **Kiovig**

- **Gamten**
- **Panzyga**
- **Xembify**
- **Cuvitru**
- **Cutaquig**
- **Hyqvia**

A2. Please see Table 2 below for the number of patients that have received the listed treatments for any disease in the past 3 months.

Table 2

<b>Treatment</b>	<b>Number of Patients</b>
Octagam	5
Gamunex	9
Intratect	9
Kiovig	Nil
Gamten	Nil
Panzyga	4
Xembify	Nil
Cuvitru	Nil
Cutaquig	Nil
Hyqvia	Nil

- Q3. In the past 3 months, how many patients have received any immunoglobulin treatment for the following diseases:**
- **Primary immunodeficiency (PID) - 2**
  - **Secondary immunodeficiency (SID) - 13**
  - **Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - 3**

A3. Please see Table 3 below for the number of patients that have received any immunoglobulin treatment for the listed diseases in the past 3 months.

Table 3

<b>Diseases</b>	<b>Number of Patients</b>
Primary immunodeficiency (PID)	2
Secondary immunodeficiency (SID)	13
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	3